We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+6.6%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$729M
AUM Growth
+$56.4M
Cap. Flow
+$52.1M
Cap. Flow %
7.15%
Top 10 Hldgs %
68%
Holding
32
New
8
Increased
10
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$34.5M
2
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$31.7M
3
AKRX
Akorn Inc
AKRX
+$23.7M
4
TVTX icon
Travere Therapeutics
TVTX
+$18.1M
5
RLYP
RELYPSA INC COM
RLYP
+$16M

Top Sells

Rank Stock Value
1
WX
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
+$37.6M
2
IPCM
IPC HEALTHCARE INC COM DTD
IPCM
+$25.3M
3
MYGN icon
Myriad Genetics
MYGN
+$19.8M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$15.8M
5
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 67.96%
2 Industrials 2.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$26.2B
$98M 13.45%
761,762
+334,972
+78% +$34.5M
ENTA icon
2
Enanta Pharmaceuticals
ENTA
$378M
$63.3M 8.68%
1,599,109
+53,012
+3% +$2.11M
TARO
3
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$47.9M 6.57%
311,234
-67,138
-18% -$10.1M
CSII
4
DELISTED
Cardiovascular Systems, Inc.
CSII
$45.9M 6.3%
1,943,054
+317,934
+20% +$9.04M
AUXL
5
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$44.6M 6.12%
+1,493,560
New +$31.7M
OFIX icon
6
Orthofix Medical
OFIX
$477M
$44.5M 6.1%
1,436,495
-34,658
-2% -$1.15M
INSY
7
DELISTED
Insys Therapeutics, Inc.
INSY
$43.4M 5.96%
2,239,834
-136,798
-6% -$2.15M
AKRX
8
DELISTED
Akorn Inc
AKRX
$42.6M 5.84%
1,173,485
+661,400
+129% +$23.7M
ABBV icon
9
AbbVie
ABBV
$455B
$33.4M 4.59%
579,100
-32,200
-5% -$1.79M
HPTX
10
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$31.9M 4.37%
1,263,034
-16,014
-1% -$398K
PTX
11
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$26.4M 3.63%
344,314
+41,829
+14% +$3.29M
ANAC
12
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$25.4M 3.49%
1,038,553
+150,347
+17% +$3.05M
OPCH icon
13
Option Care Health
OPCH
$3.36B
$21.8M 2.99%
788,488
-199,222
-20% -$6.18M
HMSY
14
DELISTED
HMS Holdings Corp.
HMSY
$21.2M 2.91%
1,123,126
+25,000
+2% +$506K
OSIR
15
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$19.9M 2.73%
1,579,561
-390,500
-20% -$5.57M
ANIP icon
16
ANI Pharmaceuticals
ANIP
$1.83B
$15.5M 2.13%
549,827
+194,551
+55% +$5.83M
RLYP
17
DELISTED
RELYPSA INC COM
RLYP
$13.9M 1.91%
+660,462
New +$16M
TVTX icon
18
Travere Therapeutics
TVTX
$5.33B
$13.9M 1.91%
+1,539,459
New +$18.1M
MACK
19
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$13.5M 1.85%
+195,340
New +$10.4M
DSCI
20
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$12.7M 1.74%
1,520,404
+68,712
+5% +$636K
PLX icon
21
Protalix BioTherapeutics
PLX
$183M
$12.2M 1.67%
+502,734
New +$14.5M
TVTY
22
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$11.2M 1.54%
698,190
-151,812
-18% -$2.57M
VCEL icon
23
Vericel Corp
VCEL
$2.43B
$6.71M 0.92%
+2,352,940
New +$7.78M
TLGT
24
DELISTED
Teligent, Inc
TLGT
$6.7M 0.92%
+71,928
New +$4.6M
HSTM icon
25
HealthStream
HSTM
$824M
$4.17M 0.57%
+173,833
New +$4.38M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, Consonance Capital Management held 32 positions worth $729M, up 8.4% from $672M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Consonance Capital Management deployed $52.1M of net new capital in Q3 2014, opening 8 new positions and adding to 10 existing holdings. Its largest new stake was AUXILIUM PHARAMCEUTICALS INC: 1,493,560 shares worth $44.6M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 74% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Taro Pharmaceutical Industries Ltd., an estimated $10.1M trimmed.

  • Consonance Capital Management's largest Q3 2014 buy was AUXILIUM PHARAMCEUTICALS INC: 1,493,560 shares worth $44.6M.
  • Consonance Capital Management added most to United Therapeutics in Q3 2014, an estimated $34.5M increase.
  • Consonance Capital Management's biggest Q3 2014 reduction was Taro Pharmaceutical Industries Ltd., cutting an estimated $10.1M.
  • Consonance Capital Management fully exited WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q3 2014, selling an estimated $37.6M.
  • Consonance Capital Management's ten largest holdings make up 68% of its $729M portfolio in Q3 2014.
  • Consonance Capital Management opened 8 new positions and closed 6 in Q3 2014.
  • Consonance Capital Management's portfolio value rose 8.4% quarter-over-quarter to $729M.

Based on Consonance Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.